Cancer News and Research

Latest Cancer News and Research

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Japanese Patent Office has granted claims in a second patent application (JP Application Number 2006-317758) for the Tuschl II patent series, entitled "RNA Interference Mediating Small RNA Molecules." In May 2008, the Japanese Patent Office granted a related set of claims in the Tuschl II patent series (JP 4 095 895).

31 Mar 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

T-cell cytolytic activity may be effective in clearing HBV infection

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge. In Western Europe and the United States, chronic HBV infection has been found in 6%󈝺% of HIV-positive patients and this co-infection is well known to be associated with increased liver-related morbidity and mortality. However, factors associated with HBV surface antigen (HbsAg) loss in HIV and HBV co-infected patients remain unclear.

31 Mar 2010

National Doctors' Day: St. Jude Children's Research Hospital honors physicians and staff

As physicians nationwide are acknowledged for their talent, sacrifice and courage on National Doctors' Day, St. Jude Children's Research Hospital honors its more than 230 staff and consulting physicians who strive to fulfill the hospital's mission each day.

31 Mar 2010

Nation's emergency physicians warn parents about dangers of prescription drug abuse

The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.

31 Mar 2010

Immigrants with mental disabilities: Reforms needed to ensure fair treatment and due process

Major reforms are needed in the nation's immigration court and detention system to ensure fair treatment and due process for immigrants with mental disabilities, according to new findings released today by Texas Appleseed, with pro bono counsel Akin Gump Strauss Hauer & Feld LLP.

31 Mar 2010

Astellas Pharma forms agreement to review certain confidential information of OSI Pharmaceuticals

OSI Pharmaceuticals, Inc. today announced that it had entered into an agreement with Astellas Pharma Inc., under which Astellas will be able to review certain confidential information related to OSI.

31 Mar 2010

2010 BIO International Convention to discuss issues that impact drug discovery and development

The 2010 BIO International Convention will feature a robust health and medical program highlighting the latest scientific breakthroughs and policy and business development issues that impact drug discovery and development. Hosted by the Biotechnology Industry Organization, the Convention will be held May 3-6, 2010 in Chicago, Ill. at McCormick Place.

31 Mar 2010

Investment report on Sunesis Pharmaceuticals

StockPreacher.com announces an investment report featuring Sunesis Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

31 Mar 2010

GSK, Isis Pharmaceuticals collaborate to develop new therapeutics for rare and serious disease

GlaxoSmithKline and Isis Pharmaceuticals, Inc. announced today a new strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious disease, including infectious diseases and some conditions causing blindness.

31 Mar 2010

Cancer Research UK launches three new prestigious awards to recognise cancer researchers

CANCER RESEARCH UK today (Tuesday) announced the launch of three new prestigious awards that will recognise world leading cancer researchers and the scientists of tomorrow.

31 Mar 2010

Indispensable role of Mindin in innate and adaptive immunity

Mindin has an indispensable role in both innate and adaptive immunity. A research group in China investigated regulation of mindin expression and the signaling pathway involved. mRNA expression of mindin was upregulated during dextran sulfate sodium induced mouse intestinal inflammation. Stimulation with CpG-ODN (a known TLR-9 ligand) induced upregulation of mindin expression in RAW 264.7 cells and significantly increased the NF-κB-luciferase activity in vitro.

31 Mar 2010

Lorillard Tobacco issues statement on FDA's TPSAC public meeting

Lorillard Tobacco Company today issued the following statement regarding the Food and Drug Administration's Tobacco Products Scientific Advisory Committee which is holding its first public meeting this week.

31 Mar 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

Hepatectomy effective for treatment of caudate lobe HCC

Caudate hepatocellular carcinoma (HCC) has a poorer prognosis than HCC originating from other lobes, due to its proximity to the portal trunk and inferior vena cava, which facilitate intrahepatic and systemic spread early in the disease. Hepatic resection is considered, in principle, to be the first choice treatment. In order to improve surgical outcome, it is necessary to evaluate the potential risk factors affecting long-term survival and to establish guidelines for the appropriate use of hepatectomy for caudate lobectomy.

31 Mar 2010

Fourth biennial BHGI Global Summit on International Breast Health

The Breast Health Global Initiative and the Latin American & Caribbean Society of Medical Oncology will convene the fourth biennial BHGI Global Summit on International Breast Health June 9-11, 2010 in Chicago, bringing together collaborating national and international organizations to address the optimization of breast health care delivery in limited-resource countries.

31 Mar 2010

BioNanomatrix awarded patent covering nanochannel arrays for high-throughput macromolecular analysis

BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, today announced the issuance of U.S. patent 7,670,770 for nanochannel arrays that enable high-throughput macromolecular analysis. Also disclosed are methods of preparing nanochannel array chips, methods of analyzing macromolecules such as entire strands of genomic DNA, and systems for implementing these methods.

31 Mar 2010

Benefits outweigh risks associated with breast cancer screening

FOR EVERY woman overdiagnosed by breast screening, two deaths will be prevented, according to a study published today (Wednesday).

31 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

Rosetta Genomics reports revenues of $150,000 for full-year 2009

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

T-cell cytolytic activity may be effective in clearing HBV infection

National Doctors' Day: St. Jude Children's Research Hospital honors physicians and staff

Nation's emergency physicians warn parents about dangers of prescription drug abuse

Immigrants with mental disabilities: Reforms needed to ensure fair treatment and due process

Astellas Pharma forms agreement to review certain confidential information of OSI Pharmaceuticals

2010 BIO International Convention to discuss issues that impact drug discovery and development

Investment report on Sunesis Pharmaceuticals

GSK, Isis Pharmaceuticals collaborate to develop new therapeutics for rare and serious disease

Cancer Research UK launches three new prestigious awards to recognise cancer researchers

Indispensable role of Mindin in innate and adaptive immunity

Lorillard Tobacco issues statement on FDA's TPSAC public meeting

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

PhRMA report: 234 medicines in development for special health care needs of children

Hepatectomy effective for treatment of caudate lobe HCC

Fourth biennial BHGI Global Summit on International Breast Health

BioNanomatrix awarded patent covering nanochannel arrays for high-throughput macromolecular analysis

Benefits outweigh risks associated with breast cancer screening

Understanding the DNA Damage Response in Innate Immunity eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in